BioCen, Grand ally of Cuban health
With nearly three decades of experience in the production, research and development of biofarmaceutical products, the Centro Nacional de Biopreparados (BioCen) today represents a fundamental ally of the Cuban health system, as it guarantees supplements and biotechnological products for use in specialized medical treatments.
In an interview given to CubaPlus magazine, its general director Dra. C. Tamara Lobaina Rodríguez, signalled that her institution constitutes the productive output of the main products of the Cuban biotechnology and pharmaceutical industry.
“The mission of BioCen – part of BioCubaFarma - is to offer contracted services for the manufacture of active pharmaceutical ingredients, parenteral liquids and lyophilisates, low volume for human use and specialized tests for quality control of biotechnological and pharmaceutical products” she added. In addition to this, she indicated, the institution investigates, develops, produces and markets culture media for plant microbiology and biotechnology, anti-anemia drugs, immunomodulators and products for the diagnosis and immunotherapy of allergies. Speaking about the work carried out in the BioCen production plants, she explained the processes of formulation, filling, inspection, and packaging of products of the Centro de Ingeniería Genética y Biotecnología, the Centro de Inmunología Molecular and the Instituto Finlay de Vacunas, among others. This institution also produces active pharmaceutical ingredients, such as Estreptokinasa Recombinante and Factor Estimulador de Colonias Granulocíticas.
She later added that since 1987 BioCen has been developing culture media, components and reagents for diagnostic microbiology, widely used in clinical laboratories for detection, isolation and identification of pathogenic bacteria, as well as for monitoring food and water hygiene, and in the pharmaceutical and biotechnology industries.
Regarding other products developed in the last 20 years, she indicated that the institution has dedicated itself to allergen immunotherapy products, an intervention that consists of administering increasing doses of allergens to the patient to induce alterations in the immune response and achieve tolerance. The standardization of these products as drugs is relatively recent, as well as their sublingual administration. Additionally, Dr. Lobaina Rodríguez referred to another of the great responsibilities of the institution she directs: the development of natural anti-anemic drugs derived from bovine blood, which are marketed in Cuba and Latin America, with proven effectiveness in preventing and treating iron deficiency anemia in the elderly, pregnant women, and children. She stressed that the work carried out by BioCen in all these years has been possible thanks to the strengths of the organization, the values and culture of its human capital, the modern technology they work with and a quality management system certified according to ISO 9001: 2015 Standards. It must be added that, with a view to perfecting its work, BioCen is immersed in making more use of its installed capacities, expanding its productive services, increasing the number of clients and developing other new and innovative products with raised added value, high international competitiveness and greater social impact.
Carretera Beltrán Km 1 1/2 , Bejucal,Mayabeque, Cuba.Teléf: (+53) 4768 2201biocen.biocubafarma.cuEmail: firstname.lastname@example.orgFacebook: /BiopreparadosTwitter: /BIOCENCU